Obsidian Therapeutics Inc.
OBXHealthcare|Biotechnology|US
$13.87
+4.26 (+44.43%)
Clinical Trials (1)
| Trial | Conditions | Phase | Status | Enrollment | Design | Drug |
|---|---|---|---|---|---|---|
| NCT06060613 Safety and Efficacy of OBX-115 in Advanced Solid Tumors | Tumor Skin, Metastatic Melanoma | P1P2 | Recruiting | 254 | Open-label | OBX-115 |